Member Info for donnodertrader

gell did that begin with a c?

darien this is what you said of ncyt 30th April

'astrazeneca and oxford uni will have a vaccine in 3 months..sell this dog quickly 25p coming'

is there a theme??

thank you. I was getting confused with fact, hope, and speculation.

so can I be clear that we have established that 'its been validated against the primer design RT- aPCR' , but that we do not know if Primerdesign has any involvement beyond validation? Is that what we know?

of course it is the result of supply and demand. the lack of figures to support the great news generated a lack of confidence and that impacted on demand. I am afraid I cannot be talked into seeing it any other way.

I do value your views. However, my opinion on this issue alone is based on observation of the impact of these last three rns(s). The last one being the best example. it was probably the best rns in the history of the stock exchange, but it was a disaster. Other things were going on in the market that day, but even so, the share should have risen considerably. But it did not. It went in the other direction. There is a common feature to the last three rns(s)m and the market response. Great information but the lack of figures.

the reason I want the numbers is because the last three rns(s) all bombed because, although the included great information, they did not include the information that the market was interested in. a big mistake three times over!

I am inclined to believe that the sales are there; but the share price suffered because the rns did not bottom out the detail.

great posts GLR The only issue I have with this great company is that they have not, as yet, learned lessons from 3 rns(s) that have contained great information, but little in the way of figures to demonstrate to the market the authenticity of their financial growth. Surely, they must realise that this cannot go on.

it has always been said on here that novacyt requires cash up front

French e 3.85

French price e 3.885

not able to buy.... is it down to interpretation? clearly the last rns gave a lot of information but did not give many specific details. what would be considered relevant to impede their buying - the theory or the figures???

yes of course they are, but my point is that much time has passed and this needs to be driven to a conclusion. I am keen that we should know what priorities will be followed for the next year.

the more I think about earlier posts, the more I am focused on the need to present a robust position at the next agm to understand more fully the drive within the company to see its excellent work be transformed into becoming a game changer for cancer patients. It is clear that the scientific and medical excellence is there; but we need to be assured of the management strength and agility to power through the developmental processes to turn theory into a practical reality for patients. This excellent work must not be lost while attention goes to the response to Covid- 19. It is critical for shareholders to be informed of the company's priorities for the next year and this should be a major component of the agm this year. If there is agreement amongst shareholders, this bb could help to develop the themes that require to be addressed at the agm! If we are looking for the company to be effective, we need to demonstrate effectiveness too.

gosh a second idiot ticked Neil's post!!!

what idiot ticked Neil's post??

neil13 I have just reviewed your earlier posts. they speak for themselves. I invite others to have a look

doesn't account for the higher holdings though!

I have been told the answer to that before. Because 5% is the relevant threshold in French law